- Home
- FTF vs TLSI Comparison
FTF vs TLSI Comparison
Compare FTF & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTF | TLSI |
|---|---|---|
| Founded | 2003 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 249.3M | 244.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FTF | TLSI |
|---|---|---|
| Price | $6.15 | $6.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 153.9K | ★ 213.6K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 11.45% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $40,207,000.00 |
| Revenue This Year | N/A | $55.06 |
| Revenue Next Year | N/A | $46.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 49.52 |
| 52 Week Low | $5.76 | $3.42 |
| 52 Week High | $6.56 | $7.95 |
Technical Indicators
Market Signals| Indicator | FTF | TLSI |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 44.00 |
| Support Level | $6.08 | $5.60 |
| Resistance Level | $6.06 | $7.20 |
| Average True Range (ATR) | 0.04 | 0.47 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 78.13 | 23.83 |
Price Performance
Historical ComparisonAbout FTF Franklin Limited Duration Income Trust of Beneficial Interest
Franklin Limited Duration Income Trust is a closed-end investment company based in the United States. It conducts its investment to provide high, current income, with a secondary objective of capital appreciation. To align with its investment objective is to invest in a diversified mix of fixed-income securities. Its portfolio is dominated by considerable investments in high-yield corporate bonds while touching upon other avenues such as senior secured floating rate corporate loans, mortgage-backed securities, commercial mortgage-backed securities, asset-backed securities, common stocks, and other short-term investments.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.